ES2179036T3 - .nticuerpos contra el receptor uroquinasa y su uso - Google Patents
.nticuerpos contra el receptor uroquinasa y su usoInfo
- Publication number
- ES2179036T3 ES2179036T3 ES91918632T ES91918632T ES2179036T3 ES 2179036 T3 ES2179036 T3 ES 2179036T3 ES 91918632 T ES91918632 T ES 91918632T ES 91918632 T ES91918632 T ES 91918632T ES 2179036 T3 ES2179036 T3 ES 2179036T3
- Authority
- ES
- Spain
- Prior art keywords
- par
- mammal
- inhibiting
- preventing
- directed against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
UN ANTICUERPO MONOCLONICO O POLICLONICO DIRIGIDO CONTRA EL RECEPTOR ACTIVADOR DEL PLASMINOGENO UROQUINASA (U-PAR), O UNA SUBSECUENCIA, ANALOGO O VARIANTE GLICOSILADA DE EL. SE DESCUBREN ANTICUERPOS LOS CUALES REACCIONAN CON U-PAR LIBRE O CON COMPLEJOS ENTRE U-PA Y U-PAR Y LOS CUALES SON CAPACES DE 1) CAPTAR U-PAR EN ELISA, O 2) DETECTAR U-PAR, P.EJ. EN DESECACION, O 3) EN ENSAYOS DE RADIOINMUNOPRECIPITACION PRECIPITAR U-PAR PURIFICADO EN FORMA INTACTA O FRAGMENTADA, O 4) SE USA PARA DETECCION INMUNOHISTOQUIMICA, P.EJ. EN INMUNOCOLORACION DE CELULAS CANCEROSAS, TAL COMO EN SECCIONES DE TEJIDO DEL FRENTE INVASIVO, O 5) INHIBE EL ENLACE DE PRO-U-PA Y U-PA ACTIVO Y POR ESTO INHIBE LA ACTIVACION DEL PLASMINOGENO EN LA SUPERFICIE CELULAR. SE DESCUBREN METODOS 1) PARA DETECTAR O CUANTIFICAR U-PAR, 2) PARA DESTINAR UN DIAGNOSTICO A UNA CELULA QUE CONTIENE UN U-PAR SOBRE LA SUPERFICIE, 3) PARA PREVENIR O CONTRARRESTAR ACTIVIDAD PROTEOLITICA EN UN MAMIFERO. METODOS PARA SELECCIONAR UNA SUSTANCIA ADECUADA PARA INHIBIR INTERACCION U-PA/U-PAR, PARA PREVENIR O CONTRARRESTAR ACTIVIDAD PROTEOLITICA LOCALIZADA EN UN MAMIFERO, PARA INHIBIR LA INVASION Y/O METASTASIS COMPRENDE EL USO DE LOS ANTICUERPOS Y DE LA INOCULACION DE RATONES DESNUDOS CON CELULAS DE CANCER HUMANO, LOS CUALES SON CONOCIDOS POR INVADIR Y/O PRODUCIR METASTASIS EN RATONES Y TENIENDO UN COLOR DISTINTIVO, P.EJ. OBTENIDO POR MEDIO DE UNA ENZIMA Y UN SUSTRATO CROMOGENICO PARA LA ENZIMA, SIENDO EL COLOR DIFERENTE DEL DE LAS CELULAS DE LOS RATONES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPCTDK9000270 | 1990-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2179036T3 true ES2179036T3 (es) | 2003-01-16 |
Family
ID=8153643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91918632T Expired - Lifetime ES2179036T3 (es) | 1990-10-18 | 1991-10-18 | .nticuerpos contra el receptor uroquinasa y su uso |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP0574391B1 (es) |
JP (1) | JPH07500486A (es) |
AT (1) | ATE219791T1 (es) |
AU (1) | AU661978B2 (es) |
CA (1) | CA2094276C (es) |
DE (1) | DE69133049T2 (es) |
ES (1) | ES2179036T3 (es) |
WO (1) | WO1992007083A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248715B1 (en) | 1993-06-01 | 2001-06-19 | Chiron Corporation | Method of treating a urokinase-type plasminogen activator-mediated disorder |
EP0802983B1 (en) | 1993-06-01 | 2003-05-02 | Chiron Corporation | Expression of urokinase plasminogen activator inhibitors |
JP2852192B2 (ja) | 1994-07-08 | 1999-01-27 | カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) | uPARのドメイン2+3のuPA結合部位および抗体 |
US6077508A (en) * | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
DE50013935D1 (de) * | 1999-04-13 | 2007-02-15 | Wilex Ag | Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor |
AU2002358921A1 (en) * | 2001-07-10 | 2003-04-28 | Omnio Ab | Novel drug targets for arthritis |
JPWO2003014394A1 (ja) * | 2001-08-03 | 2004-11-25 | 旭メディカル株式会社 | 生体適合性評価法 |
JP2004137151A (ja) * | 2002-10-15 | 2004-05-13 | Keio Gijuku | 脳腫瘍の治療・診断薬 |
TW200813091A (en) * | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
KR101065571B1 (ko) * | 2006-09-28 | 2011-09-19 | 가부시키가이샤 시마즈세이사쿠쇼 | 파라핀 포매 표본의 탈파라핀법 및 파라핀 포매 표본의 해석법 |
WO2008073312A2 (en) | 2006-12-08 | 2008-06-19 | Attenuon, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
WO2010118979A1 (en) * | 2009-04-07 | 2010-10-21 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
US10126216B2 (en) | 2011-02-17 | 2018-11-13 | Ventana Medical Systems, Inc. | Method for tissue sample fixation |
US10539487B2 (en) | 2010-03-04 | 2020-01-21 | Ventana Medical Systems, Inc. | Systems and methods for monitoring tissue sample processing |
AU2011222501B2 (en) | 2010-03-04 | 2014-05-01 | Ventana Medical Systems, Inc. | Processing system for processing specimens using acoustic energy |
MA41842A (fr) * | 2015-03-31 | 2018-02-06 | Oblique Therapeutics Ab | Nouveaux procédés de sélection d'épitope |
GB201617002D0 (en) | 2016-10-06 | 2016-11-23 | Oblique Therapeutics Ab | Multi-protease method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923807A (en) * | 1984-05-18 | 1990-05-08 | New England Medical Center Hospitals Inc. | Arg-Serpin human plasminogen activator inhibitor designated PAI-2 |
DE3902021A1 (de) * | 1989-01-20 | 1990-07-26 | Entec | Verwendung von antipeptidergen mitteln, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen prostatakarzinoms |
WO1990012091A1 (en) * | 1989-04-07 | 1990-10-18 | Cancerforskningsfondet Af 1989 | Urokinase-type plasminogen activator receptor |
-
1991
- 1991-10-18 WO PCT/DK1991/000319 patent/WO1992007083A1/en active IP Right Grant
- 1991-10-18 AT AT91918632T patent/ATE219791T1/de active
- 1991-10-18 DE DE69133049T patent/DE69133049T2/de not_active Expired - Lifetime
- 1991-10-18 EP EP91918632A patent/EP0574391B1/en not_active Expired - Lifetime
- 1991-10-18 JP JP3517643A patent/JPH07500486A/ja active Pending
- 1991-10-18 AU AU87572/91A patent/AU661978B2/en not_active Ceased
- 1991-10-18 CA CA002094276A patent/CA2094276C/en not_active Expired - Lifetime
- 1991-10-18 ES ES91918632T patent/ES2179036T3/es not_active Expired - Lifetime
- 1991-10-18 EP EP02013976A patent/EP1281404A3/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPH07500486A (ja) | 1995-01-19 |
WO1992007083A1 (en) | 1992-04-30 |
EP1281404A2 (en) | 2003-02-05 |
CA2094276A1 (en) | 1992-04-19 |
DE69133049T2 (de) | 2003-01-02 |
EP1281404A3 (en) | 2004-04-07 |
EP0574391A1 (en) | 1993-12-22 |
CA2094276C (en) | 2005-08-23 |
DE69133049D1 (de) | 2002-08-01 |
AU8757291A (en) | 1992-05-20 |
EP0574391B1 (en) | 2002-06-26 |
ATE219791T1 (de) | 2002-07-15 |
AU661978B2 (en) | 1995-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2179036T3 (es) | .nticuerpos contra el receptor uroquinasa y su uso | |
DE69033653D1 (de) | Plasminogen-aktivator-rezeptor vom urokinasetyp | |
ES442140A1 (es) | Perfeccionamientos en los asientos para soportar pesos. | |
ATE137405T1 (de) | Transdermales system | |
ES222235U (es) | Elemento de union. | |
DK0573545T3 (da) | Monoklonale antistoffer mod receptor-inducerede bindingssteder | |
FI903464A0 (fi) | Foerfarande foer oxiderande denaturering av proteinanalyter. | |
ATE239784T1 (de) | Monoklonale antikörper gegen isozyme der thymidinkinase | |
FI873410A0 (fi) | Kahden uuden hybridooman tuottamia apolipoproteiini-B-spesifisiä monoklonaalisia vasta-aineita | |
DE3484552D1 (de) | Dachbelagsmaterial. | |
ATE72992T1 (de) | Antikoerper nuetzlich als fuehrungsagenzien und konjugate die sie enthalten. | |
IT7829300A0 (it) | Composto fungicida o crittogamico di protezione specialmente per il controllo della peronospora della vite e metodo di uso. | |
Mattila | Resources leveling of linear schedules: A mathematical approach using integer linear programming | |
DE69032745T2 (de) | Festes substrat für peptidsynthese | |
DK329789D0 (da) | Monoklonalt antistof | |
FR2415565A1 (fr) | Perfectionnement a un wagon | |
ES2053704T3 (es) | Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales. | |
EP0437547A4 (en) | Monoclonal antibodies against receptor-induced binding sites | |
IT1114642B (it) | Valvola di controllo della direzione e della portata,sensibile al carico | |
EP0284413A3 (en) | Derivative of a fibrinolytic enzyme | |
DE3888031T2 (de) | Homocyclostatin und Cyclostatin enthaltende Polypeptide als Antihypertensiva. | |
EP0486325A3 (en) | Process for selective removal of salivary alpha-amylase and assay for pancreatic alpha-amylase | |
KR940005284A (ko) | 면역친화성 크로마토그래피에 의한 플라스미노겐 활성화제 억제제 2의 정제방법 | |
SE7707009L (sv) | Fjederelement for liggmobler | |
SE9604298L (sv) | Blästrande diskmaskin med bräddavlopp |